The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation
Recruiting
REACT-AF is a multicenter prospective, randomized, open-label, blinded endpoint (PROBE design), controlled trial comparing the current Standard Of Care (SOC) of continuous Direct Oral Anticoagulation (DOAC) use versus time-delimited (1 month) DOAC guided by an AF-sensing Smart Watch (AFSW) in participants with a history of paroxysmal or persistent Atrial Fibrillation (AF) and low-to-moderate stroke risk.
Gender:
All
Ages:
Between 22 years and 85 years
Trial Updated:
11/30/2023
Locations: University of Illinois Chicago, Chicago, Illinois
Conditions: Atrial Fibrillation
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
Recruiting
This study evaluates navtemadlin as maintenance treatment for patients with advanced or recurrent endometrial cancer (EC) who have achieved complete response or partial response on chemotherapy. The study will be conducted in 2 parts. Part 1 will evaluate safety and efficacy of two different doses of navtemadlin alongside an observational control arm to determine the Phase 3 navtemadlin dose. Part 2 will evaluate the efficacy and safety of navtemadlin Phase 3 dose compared to placebo.
Gender:
Female
Ages:
18 years and above
Trial Updated:
11/30/2023
Locations: Dr. Sudarshan K. Sharma, Ltd., Hinsdale, Illinois
Conditions: Endometrial Cancer
A Multicenter, Open-label Phase 3 Study: Ambulatory Blood Pressure Monitoring in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Treated With Remibrutinib up to 12 Weeks.
Recruiting
The primary objective of the study is to rule out an increase of >3mmHg in 24-hour average Systolic Blood Pressure at steady state (Week 4) compared to baseline. ABPM was chosen for the blood pressure assessment in this trial as recommended by the FDA for drugs intended for chronic use (Assessment of Pressor Effects of Drugs Guidance for Industry (FDA 2022)).
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
11/30/2023
Locations: Novartis Investigative Site, Skokie, Illinois
Conditions: Chronic Spontaneous Urticaria
Study of MB-102 (Relmapirazin) and the Use of the MediBeacon® Transdermal GFR Measurement System Using the TGFR Reusable Sensor With Disposable Adhesive Ring
Recruiting
The objective of this study is to establish that the MB-102 transdermal fluorescence-measured Glomerular Filtration Rate (GFR) using the MediBeacon® Measurement System with the Transdermal Glomerular Filtration Rate (TGFR) reusable sensor with disposable adhesive ring is comparable to the plasma-measured MB-102 GFR in normal and compromised renal function participants with different skin color types.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/30/2023
Locations: Research by Design, LLC, Chicago, Illinois
Conditions: Kidney Diseases, Kidney Injury, Kidney Failure
Efficacy and Safety of SYNB1934 in Patients With PKU (SYNPHENY-3)
Recruiting
This is a 3-part, adaptive study consisting of a dose-escalating period (DEP) of up to 15 weeks (Part 1), followed by a 4-week, double-blind, placebo-controlled randomized withdrawal period (RWP) (Part 2), and an open-label extension (OLE) (Part 3) of up to 36 months.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/30/2023
Locations: Ann & Robert H. Lurie Children's Hospital of Chicago, Pediatrics, Chicago, Illinois
Conditions: Phenylketonuria
ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE
Recruiting
The primary objective of this study is to assess the efficacy of a single dose of ravulizumab IV compared with placebo in reducing the risk of the clinical consequences of AKI (MAKE) at 90 days in adult participants with CKD who undergo non-emergent cardiac surgery with CPB.
Gender:
All
Ages:
Between 18 years and 90 years
Trial Updated:
11/30/2023
Locations: Research Site, Chicago, Illinois
Conditions: Chronic Kidney Disease, CKD, Cardiac Disease, Cardiopulmonary Bypass
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Recruiting
This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment alone in improving survival in patients with stage I and II classical Hodgkin lymphoma. Brentuximab vedotin is in a class of medications called antibody-drug conjugates. It is made of a monoclonal antibody called brentuximab that is linked to a cytotoxic agent called vedotin. Brentuximab attaches to CD30 posi... Read More
Gender:
All
Ages:
Between 5 years and 60 years
Trial Updated:
11/30/2023
Locations: Rush - Copley Medical Center, Aurora, Illinois
Conditions: Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)
Recruiting
The primary purpose of this study is to compare pembrolizumab/vibostolimab to pembrolizumab with respect to recurrence-free survival (RFS). The primary hypothesis is that pembrolizumab/vibostolimab is superior to pembrolizumab with respect to RFS as assessed by the investigator in participants with high-risk resected Stage IIB, IIC, III and IV melanoma.
Gender:
All
Ages:
12 years and above
Trial Updated:
11/30/2023
Locations: Northwestern Memorial Hospital ( Site 0109), Chicago, Illinois
Conditions: Melanoma
Testing Feasibility of Medication Adherence Problem Solving for Hypertension
Recruiting
Adherence to medications for high blood pressure is key to improving blood pressure control and reducing the impact of cardiovascular disease. This project will test the feasibility of a tailored telehealth intervention to help patients improve adherence to blood pressure medication.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/30/2023
Locations: Rush University Medical Center, Chicago, Illinois
Conditions: Hypertension, Adherence, Medication
A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer
Recruiting
The goal of this clinical trial is to test if the addition of botensilimab to standard chemotherapy improves the efficacy compared to just chemotherapy alone in participants with metastatic pancreatic cancer. One group of participants will only receive chemotherapy while a second group of participants will receive botensilimab and chemotherapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/30/2023
Locations: Illinois Cancer Specialists, Arlington Heights, Illinois
Conditions: Metastatic Pancreatic Ductal Adenocarcinoma
Alzheimer's Disease Neuroimaging Initiative 4
Recruiting
Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging Initiative (ADNI) Study has been to validate biomarkers for Alzheimer's disease (AD) clinical trials. ADNI4 continues the previously funded ADNI1, ADNI-GO, ADNI2, and ADNI3 studies that have combined public/private collaborations between academia and industry to determine the relationships between the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of AD.
Gender:
All
Ages:
Between 55 years and 90 years
Trial Updated:
11/30/2023
Locations: Rush University Memory Clinic, Chicago, Illinois
Conditions: Mild Cognitive Impairment, Alzheimer Disease, Dementia
Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis
Recruiting
The purpose of this study is to evaluate the safety and efficacy of ALXN1720 for the treatment of generalized MG (gMG) in adults with autoantibodies against acetylcholine receptor (AChR).
Gender:
All
Ages:
18 years and above
Trial Updated:
11/30/2023
Locations: Research Site, Springfield, Illinois
Conditions: Generalized Myasthenia Gravis